{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:57:24Z","timestamp":1753891044773,"version":"3.41.2"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972690, 81000914, 81272526"],"award-info":[{"award-number":["81972690, 81000914, 81272526"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.563622","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T06:56:51Z","timestamp":1604645811000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency"],"prefix":"10.3389","volume":"11","author":[{"given":"Shumin","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiufeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqiu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zibing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the Treatment of Non\u2013Small-Cell Lung Cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the Tumor Microenvironment in PD-L1\/PD-1-mediated Tumor Immune Escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nm0598-627","article-title":"B Cells Inhibit Induction of T Cell-Dependent Tumor Immunity","volume":"4","author":"Qin","year":"1998","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-019-0613-1","article-title":"B Cell Depletion or Absence Does Not Impede Anti-Tumor Activity of PD-1 Inhibitors","volume":"7","author":"Damsky","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti\u2013PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2015.10.009","article-title":"Immune Suppressive Mechanisms in the Tumor Microenvironment","volume":"39","author":"Munn","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00646.x","article-title":"B-lymphocyte Contributions to Human Autoimmune Disease","volume":"223","author":"Yanaba","year":"2008","journal-title":"Immunol Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B Cell Changes Predict Autoimmunity Following Combination Immune Checkpoint Blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14841","article-title":"Systematic Review of Rituximab for Autoimmune Diseases: A Potential Alternative to Intravenous Immune Globulin","volume":"58","author":"MacIsaac","year":"2018","journal-title":"Transfusion"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and Tolerability of Pembrolizumab in Patients With Relapsed\/Refractory Primary Mediastinal Large B-cell Lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1774314","DOI":"10.1080\/2162402X.2020.1774314","article-title":"Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review","volume":"9","author":"Wagner","year":"2020","journal-title":"Oncoimmunology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.563622\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T06:56:54Z","timestamp":1604645814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.563622\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":12,"alternative-id":["10.3389\/fimmu.2020.563622"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.563622","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2020,11,6]]},"article-number":"563622"}}